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Zusammenfassung
Hintergrund: Das Magenkarzinom wird häufig im fortge-
schrittenen Stadium diagnostiziert, und nur etwa 10%
der Patienten überleben 2 Jahre. Aktuelle Chemothera-
pien zeigen eine hohe therapiebedingte Toxizität. Es ist
daher von großer Bedeutung, diejenigen Patienten zu
identifizieren, die von einer bestimmten Therapie profi-
tieren, um anderen Patienten die Nebenwirkungen einer
solchen Therapie zu ersparen. Patienten und Methoden:
2 Patienten mit fortgeschrittenem Magenkarzinom erhiel-
ten wiederholt eine Kombinationschemotherapie aus 
5-FU/Cisplatin. Genomische DNS wurde aus Tumorgewe-
be und Leukozyten isoliert. Genotypanalysen von Genen,
die am Metabolismus der Substanzen und am DNS-Re-
paraturprozess beteiligt sind, wurden mithilfe einer PCR-
RFLP-Methode durchgeführt. Das Gen der Dihydropyri-
midindehydrogenase (DPD) wurde direkt sequenziert. Er-
gebnisse: Beide Patienten zeigten ein deutlich verlänger-
tes Überleben von 51 bzw. 29 Monaten. Genotypen des
5-FU-Zielenzyms Thymidylatsynthase, die mit einem ver-
besserten Ansprechen assoziiert sind, konnten in beiden
Patienten nachgewiesen werden. DPD-Varianten, die mit
einer erhöhten Toxizität verbunden sind, wurden nicht
beobachtet. Zusätzlich konnten bei beiden Patienten Ge-
notypen in Cisplatin metabolisierenden Genen gefunden
werden, die eine prolongierte Wirkung der Substanz be-
dingen. Schlussfolgerungen: Durch Genotypanalysen in
Genen des 5-FU- und Cisplatin-Metabolismus konnte ein
spezifisches pharmakogenetisches Profil identifiziert wer-
den, das möglicherweise die Ursache eines außerge-
wöhnlich guten Therapieeffektes in 2 Patienten mit fort-
geschrittenem Magenkarzinom ist. 
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Summary
Background: Gastric cancer is often diagnosed in the
metastatic stage, and only 10% of patients survive for as
long as 2 years. Current chemotherapy regimens show
significant treatment-related toxicities. It is crucial to
identify the patients that will benefit most from certain
chemotherapy regimens in order to avoid unnecessary
side effects. Patients and Methods: 2 patients with ad-
vanced gastric cancer repeatedly received 5-FU/cisplatin
combination chemotherapy. Genomic DNA was extract-
ed from tumor tissue and mononuclear blood cells.
Genotype analysis of genes of metabolizing and DNA re-
pair enzymes was carried out using a PCR-RFLP tech-
nique. Direct sequencing was used to identify mutations
of the gene dihydropyrimidine dehydrogenase (DPD).
Results: Prolonged survival of 51 and 29 months, respec-
tively were observed in our 2 patients. Both patients
were positive for genotypes of thymidylate synthase –
the target enzyme of 5-FU – that are associated with im-
proved drug response. DPD variants connected with in-
creased toxicity were not observed. However, both pa-
tients also showed genotypes in cisplatin metabolizing
enzymes which enhance the effect of the drug. Conclu-
sion: Genotype analysis in drug metabolizing enzymes
of 5-FU and cisplatin provide a possible explanation for
extraordinary therapy effects observed in 2 patients with
advanced gastric cancer. 
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Introduction
Gastric cancer is often diagnosed in advanced stages of the
disease and is therefore associated with a poor prognosis. The
median survival is as little as 6–8 months, and less than 10% of
patients with metastatic disease survive for as long as 2 years
[1]. Current treatment regimens – including epirubicin,
methotrexat, platinum and 5-FU – are often highly toxic [2].
Recently, additional drugs such as irinotecan, taxanes and ce-
tuximab have been introduced to palliative treatment of gas-
tric cancer. The high toxicity and limited benefits of current
chemotherapies for most gastric cancer patients require a
careful selection of patients suitable for treatment. 
Currently, there are no efficient clinical, pathological or mole-
cular markers to distinguish between responders and non-re-
sponders in relation to certain chemotherapy regimens used in
gastric cancer. Pharmacogenetic analysis utilizes information
on metabolic variations of administered chemotherapeutic
drugs to predict clinical outcome. A combination of cisplatin
and 5-FU is widely used in gastric cancer patients. Several
functional genetic polymorphisms have been described for
metabolizing enzymes of these substances such as thymidylate
synthase (TS), glutathione S-transferase (GST) and excision
cross complementing gene (ERCC) [3]. 
Here, we report on an extraordinary response to 5-FU/cis-
platin combination chemotherapy in 2 gastric cancer patients.
We further provide information on pharmacogenetic analysis
demonstrating its potential as a predictor for clinical outcome
in gastric cancer. 
Case Reports
Clinical Observations
A 51-year-old female patient (patient A) was diagnosed with advanced
gastric cancer in February 2001. Initial surgery revealed advanced peri-
toneal carcinomatosis, and parts of the omentum, the adnexes and a
Krukenberg’s tumor were removed. A postoperative CT scan demon-
strated advanced peritoneal carcinomatosis and a thickening of the stom-
ach wall, but no further distant metastases. 6 weeks after surgery, a com-
bination chemotherapy of 5-FU and cisplatin was initiated. The patient
received 200 mg/m2 leucovorin followed by 2000 mg/m2 5-FU once week-
ly and 50 mg/m2 cisplatin every other week for 6 weeks (one cycle).
Tumor assessment after 3 cycles of chemotherapy revealed that all tumor-
related lesions had disappeared. Approximately 1 year after having been
diagnosed, the patient once again showed tumor progression and a thick-
ening of the stomach wall. The patient received 2 more cycles of
chemotherapy followed by a Billroth II resection and remained disease-
free for 10 months. In May 2004, the disease recurred in the remaining
stomach and the abdominal cavity. The patient received 3 more cycles of
5-FU/cisplatin and did not show any disease progression until November
2004. At that point, the chemotherapy regimen was changed to 5-FU, leu-
covorin and mitomycin C. The patient last visited the hospital in May
2005, 51 months after the initial diagnosis of stomach cancer and peri-
toneal carcinomatosis. During the entire treatment, no major hematolog-
ical or gastrointestinal toxicities were observed. The patient did not
demonstrate any hepatic or renal failure. 
Patient B, a 60-year-old female patient, was diagnosed with stomach can-
cer in December 2002 after having reported constantly increasing diges-
tive problems and pains in the upper abdomen. Clinical examination re-
vealed a 22 × 26 mm mass on the right abdominal wall. The stomach was
removed (R2 resection) in an attempt to prevent gastric outlet obstruc-
tion, and examination of biopsies taken from the mass on the abdominal
wall confirmed metastasized stomach cancer. 7 weeks after surgery, pallia-
tive chemotherapy with 5-FU/cisplatin as described above was started.
After 2 cycles of combination chemotherapy, CT scans showed only mini-
mal residual disease, and complete response was obtained after 3 cycles,
followed by a disease-free interval of 23 months. 1 month prior to a sched-
uled follow-up visit at the outpatient clinic, patient B noticed significant
weight loss and new abdominal pain. In February 2005, the disease pro-
gressed including retroperitoneal lymph node metastases, and the patient
was put back on 5-FU/cisplatin combination chemotherapy. Upon last pa-
tient contact in May 2005, no disease progression was observed. In addi-
tion to the remarkable response to the treatment, patient B experienced
severe side effects in the form of WHO grade-III diarrhea. The diarrhea
was managed with saline infusions and oral loperamide. Since the patient
had responded well to the first therapy cycle, we aimed to continue the
chemotherapy regimen. Tumor response was evaluated according to the
RECIST criteria. Toxicity was graded based on the WHO toxicity criteria.
Both patients gave informed consent to perform genotype analysis. 
Patients A and B showed remarkable responses to 5-FU/cisplatin
chemotherapy with prolonged time to progression and survival times of
51 months and 29 months, respectively.
Pathological Examination and Genotype Analysis
Patient A showed a poorly differentiated adenocarcinoma of the stomach.
The tumor of patient B was moderately differentiated. For genotyping,
DNA was extracted from both tumor sections and peripheral mononu-
clear cells. Genotyping was performed using a PCR based restriction frag-
ment length polymorphism (RFLP) technique and direct sequencing [4,
5]. Genetic polymorphisms were examined in the following genes in-
volved in the metabolism of cisplatin and 5-FU: thymidylate synthase
(TS), dihydropyrimidine dehydrogenase (DPD), glutathione S-transferase
P1 (GSTP1) and excision repair cross complementing gene 1 (ERCC1).
The genotypes are presented in table 1. Between tumor and host DNA,
no genotype differences were observed.
Discussion
Both patients experienced prolonged survival and benefited
significantly from repeated 5-FU/cisplatin combination
chemotherapy. We analyzed functional genetic variations in
the DNA sequence of metabolizing enzymes of 5-FU (TS-3’,
TS-5’, DPD) and cisplatin (GSTP1-105, ERCC1-118). 
The TS-3’ 1494del6 (-) variant and the TS-5’ 2R and 3RC vari-
ants have been associated with decreased TS expression [6, 7].
Several reports link low TS expression levels to a favourable
outcome of 5-FU based chemotherapy in gastrointestinal tu-
mors including gastric cancer [8–10]. Patient A had TS geno-
types (TS-3’ and TS-5’) associated with decreased TS levels,
which may have enhanced the 5-FU action. Interestingly, no
severe side effects were observed in this patient. High-grade
hematological and gastrointestinal side effects have been de-
scribed in patients with DPD deficiency [11]. The polymor-
phism in exon 14 of the DPD gene, that shows the highest fre-
quency of known DPD polymorphisms and has been linked to
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even fatal toxicity, was not identified in our patients [4]. The
dramatic side effects seen in DPD deficient patients are due to
accumulation of active metabolites of 5-FU, since DPD clears
more than 80% of 5-FU in the liver. However, patient B expe-
rienced grade-III diarrhea. Such an association between 5-FU
toxicity and TS genotype contrary to the effects on the tumor
has been reported before [12]. 
Although both patients harbored TS genotypes favoring
tumor response and increased toxicity, only patient B demon-
strated significant side effects. This reflects obvious limitations
of a pharmacogenetic approach focusing on key enzymes.
Functional variations in additional players such as methylen-
tetrahydrofolate reductase (MTHFR) or dUTP dinucleotido-
hydrolase (dUTPase) may have neutralized the 5-FU effect in
patient A but enhanced its power in patient B. Furthermore, 
it has to be considered that responses seen in both patients
are the results of a combination chemotherapy of 5-FU and
cisplatin.
The detoxifying effect of GSTP1 on cisplatin is well estab-
lished [13]. The valine variant of a single nucleotide polymor-
phism (SNP) within exon 5 of the GSTP1 gene could be linked
to superior survival in colorectal cancer patients that received
5-FU/platinum chemotherapy [14]. The favorable GSTP1 vari-
ant was detected in its homozygous form in patient A. Patient
B was heterozygous for this polymorphism. In addition, both
patients demonstrated ERCC1 genotypes that have been
linked to impaired DNA repair capacity [15]. Taken together,
both patients demonstrated genotypes that enhance the plat-
inum effect due to less efficient detoxification of the adminis-
trated drug (GSTP1 genotype) and reduced repair of cis-
platin-induced DNA adducts by the nucleotide excision repair
pathway (ERCC1 genotype). 
In conclusion, both patients with advanced gastric cancer 
experienced significant clinical benefit and extraordinary pro-
longed survival following 5-FU/cisplatin combination chemo-
therapy. Pharmacogenetic analysis of metabolizing enzymes
provided some insight into possible mechanisms underlying
this success. Since new drugs such as oxaliplatin [16] and do-
cetaxel [17] have recently been shown to be effective in the
treatment of patients with gastric cancer, pharmacogenetics
appear to be a promising tool to tailor chemotherapy in these
patients in the future. 
The clinical impact of pharmacogenetic analysis in patients with
advanced gastric cancer is currently evaluated in large clinical
trials. Our preliminary findings regarding polymorphisms in the
TS and GSTP1 gene and response to 5-FU/cisplatin chemother-
apy in these patients need to be confirmed before this informa-
tion should be incorporated into clinical routine.
TS-3’ TS-5’ TS-SNP ERCC1-118 GSTP1–105 DPD
Patient A -/- 2R/3R C C/T Val/Val wt/wt
Patient B -/+ 2R/3R C T/T Ile/Val wt/wt
Val: valine, Ile: isoleucin, wt: wild type, (-): TS-3’ 1494del6, (+): TS-3’ 1494ins6.
Table 1. Genotypes of patient A and patient B
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